Mycoplasma genitalium: yet another challenging STI

The Lancet Infectious Diseases

Volumn 17, Issue 8, 2017, Pages 795-796

  Jensen, Jørgen Skov ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; DOXYCYCLINE; GEPOTIDACIN; LEFAMULIN; MACROLIDE; MOXIFLOXACIN; PRISTINAMYCIN; RIBOSOME RNA; RNA 23S; SITAFLOXACIN; SPECTINOMYCIN; ZOLIFLODACIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CHLAMYDIA TRACHOMATIS; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; GENE MUTATION; GONORRHEA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA GENITALIUM; MYCOPLASMA GENITALIUM INFECTION; NEISSERIA GONORRHOEAE; NOTE; OPERON; PREVALENCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYMPTOMATOLOGY; WORLD HEALTH ORGANIZATION;

HUMANS; MYCOPLASMA GENITALIUM; NEISSERIA GONORRHOEAE; PREVALENCE; SEXUALLY TRANSMITTED DISEASES;

EID: 85022086936     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30364-X     Document Type: Note

References (14)

1. Unemo, M, Bradshaw, CS, Hocking, JS, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis, 2017 published online July 9. http://dx.doi.org/10.1016/S1473-3099(17)30310-9.
2. Newman, L, Rowley, J, Vander, HS, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE, 10, 2015, e0143304.
3. Unemo, M, Jensen, JS, Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol 14 (2017), 139–152.
4. Jensen, JS, Bradshaw, C, Management of Mycoplasma genitalium infections—can we hit a moving target?. BMC Infect Dis, 15, 2015, 343.
5. Sonnenberg, P, Ison, CA, Clifton, S, et al. Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Int J Epidemiol 44 (2015), 1982–1994.
6. Short, VL, Totten, PA, Ness, RB, Astete, SG, Kelsey, SF, Haggerty, CL, Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 48 (2009), 41–47.
7. Lau, A, Bradshaw, CS, Lewis, D, et al. The Efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis 61 (2015), 1389–1399.
8. Jensen, JS, Bradshaw, CS, Tabrizi, SN, Fairley, CK, Hamasuna, R, Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis 47 (2008), 1546–1553.
9. Read, TR, Fairley, CK, Tabrizi, SN, et al. Azithromycin 1.5g over 5 days compared to 1g single dose in urethral Mycoplasma genitalium: impact on treatment outcome and resistance. Clin Infect Dis 64 (2017), 250–256.
10. Jensen, JS, Cusini, M, Gomberg, M, Moi, H, 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol 30 (2016), 1650–1656.
11. Walker, J, Fairley, CK, Bradshaw, CS, et al. Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian women. Clin Infect Dis 56 (2013), 1094–1100.
12. Björnelius, E, Magnusson, C, Jensen, JS, Mycoplasma genitalium macrolide resistance in Stockholm, Sweden. Sex Transm Infect 93 (2017), 167–168.
13. Murray, GL, Bradshaw, CS, Bissessor, M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis 23 (2017), 809–812.
14. Falk, L, Jensen, JS, Successful outcome of macrolide-resistant Mycoplasma genitalium urethritis after spectinomycin treatment: a case report. J Antimicrob Chemother 72 (2017), 624–625.